Ecor1 Capital Decreased Agios Pharmaceuticals (AGIO) Position, 5 Analysts Bullish TORC OIL AND GAS LTD (TSE:TOG)

May 31, 2017 - By Louis Casey

Ecor1 Capital Llc decreased Agios Pharmaceuticals Inc (AGIO) stake by 88.35% reported in 2016Q4 SEC filing. Ecor1 Capital Llc sold 176,700 shares as Agios Pharmaceuticals Inc (AGIO)’s stock declined 9.11%. The Ecor1 Capital Llc holds 23,300 shares with $972,000 value, down from 200,000 last quarter. Agios Pharmaceuticals Inc now has $2.20 billion valuation. The stock declined 0.85% or $0.4 reaching $46.67 per share. About 480,069 shares traded. Agios Pharmaceuticals Inc (NASDAQ:AGIO) has risen 8.52% since May 31, 2016 and is uptrending. It has underperformed by 8.18% the S&P500.

Among 6 analysts covering Torc Oil & Gas (TSE:TOG), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Torc Oil & Gas had 23 analyst reports since August 13, 2015 according to SRatingsIntel. As per Friday, December 16, the company rating was maintained by RBC Capital Markets. The company was maintained on Tuesday, December 15 by RBC Capital Markets. The stock has “Outperform” rating by Scotia Capital on Wednesday, November 9. The company was maintained on Friday, March 3 by Scotia Capital. On Friday, August 19 the stock rating was maintained by TD Securities with “Buy”. The firm earned “Buy” rating on Friday, December 16 by TD Securities. See TORC OIL AND GAS LTD (TSE:TOG) latest ratings:

03/03/2017 Broker: Scotia Capital Rating: Outperform New Target: $10.25 Maintain
03/03/2017 Broker: TD Securities Rating: Buy Old Target: $11.50 New Target: $12.00 Target Up
25/01/2017 Broker: IBC Rating: Old Target: $9.50 New Target: $9.00 Target Down
16/12/2016 Broker: RBC Capital Markets Rating: Outperform New Target: $10.00 Maintain
16/12/2016 Broker: TD Securities Rating: Buy New Target: $10.50 Maintain

Among 13 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 8 have Buy rating, 0 Sell and 5 Hold. Therefore 62% are positive. Agios Pharmaceuticals had 22 analyst reports since July 23, 2015 according to SRatingsIntel. The firm has “Hold” rating by Canaccord Genuity given on Friday, August 7. Oppenheimer upgraded the shares of AGIO in report on Tuesday, January 17 to “Outperform” rating. The rating was initiated by Needham with “Buy” on Monday, October 24. The company was initiated on Wednesday, March 2 by Janney Capital. As per Monday, November 9, the company rating was maintained by TH Capital. The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) earned “Buy” rating by Suntrust Robinson on Wednesday, May 18. The firm has “Market Perform” rating given on Monday, December 7 by Leerink Swann. The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) earned “Neutral” rating by BTIG Research on Friday, August 19. Roth Capital maintained Agios Pharmaceuticals Inc (NASDAQ:AGIO) rating on Wednesday, August 5. Roth Capital has “Hold” rating and $114 target. On Wednesday, March 30 the stock rating was initiated by SunTrust with “Buy”.

Since February 16, 2017, it had 0 buys, and 11 sales for $22.21 million activity. Schenkein David P sold $150,180 worth of stock or 3,000 shares. Biller Scott sold 6,438 shares worth $354,090. Cantley Lewis Clayton Jr. sold 2,036 shares worth $108,132. On Friday, March 3 the insider NELSEN ROBERT sold $2.06M.